Navigation Links
CVS Caremark Sponsored Research Finds FDA Drug Warnings Can Have Immediate Negative Impact on Medication Adherence, Even if Not Related to Safety
Date:5/23/2012

WOONSOCKET, R.I., May 23, 2012 /PRNewswire/ -- New research sponsored by CVS Caremark examined the effects of Food and Drug Administration (FDA) drug warnings on medication adherence when the warnings are not delivered with clear clinical recommendations. The research found that immediately following a high-profile FDA communication questioning the efficacy for a cholesterol-lowering drug, the monthly level of patients who stopped filling their prescription increased by nearly 6 percent. In addition, of those patients who stopped taking the drug after the FDA warning, only 16.5 percent switched to another clinically appropriate therapy.

(Photo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO)

"These findings suggest that when an FDA communication about a prescription drug is widely reported in the news media and is not related to a safety issue or accompanied by clear guidelines about how to apply this information, the resulting confusion can bluntly reduce overall rates of treatment," said Niteesh Choudhry, MD, PhD of Brigham and Women's Hospital, a study co-author.  "Furthermore, if patients respond to this information by stopping therapy altogether and do not switch to another clinically appropriate medication there could be a negative impact on health outcomes which runs contrary to the intent of the initial communication."  

Researchers from Harvard University, Brigham and Women's Hospital and CVS Caremark, reviewed the impact of an FDA communication made on January 25, 2008 regarding the cholesterol-lowering medication, ezetimibe. The FDA issued an early communication after results from the ENHANCE trial indicated that adding ezetimibe (known as either Zetia or the ezetimibe-simvastatin combination, Vytorin) to a treatment regimen including simvastatin did not appear to improve patient outcomes. The FDA raised questions about the effectiven
'/>"/>

SOURCE CVS Caremark
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CVS Caremark Reports Record First Quarter Results
2. CVS Caremark Corporation to Hold First Quarter 2012 Conference Call
3. CVS Caremark Ranks Among Top 25 Most Reputable Companies in America on Forbes List
4. CVS Caremark Corporation Announces Quarterly Dividend
5. CVS Caremarks Chief Medical Officer Troyen Brennan is Named to the National Commission on Physician Payment Reform
6. CVS Caremarks MinuteClinic to Deploy Allscripts EHR Nationally
7. CVS Caremark to Present at the RBC Healthcare Conference
8. Report: CVS Caremark Contributes Billions to Rhode Island Economy
9. NCPA Comments on FTC Action Against CVS Caremark, Vows to Continue PBM Transparency Efforts
10. FTC Ends Investigation of CVS Caremark
11. CVS Caremark Corporation Settles FTC Deceptive Pricing Charges
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... , Nov. 28, 2014 The market for ... reach 7.9 billion dollars in 2014 according to Kalorama ... existing equipment and growing incidence of disease are driving ... X-Ray and Digital X-Ray: World Market Analysis ... X-Ray: World Market Analysis can be obtained at: ...
(Date:11/28/2014)... ATLANTA , Nov. 28, 2014 ... (Alimera), a pharmaceutical company that specializes in the ... has entered into a Securities Purchase Agreement with ... pursuant to which Alimera will issue shares of ... price of approximately $50.0 million upon the satisfaction ...
(Date:11/27/2014)... , Nov. 27, 2014  Javon Bea Mercy ... 19, faculty and staff at Janesville Craig High School ... from Mercy Health System physicians and Janesville ... Fire Departments and the Janesville ... Care Program, dedicated to providing schools and other organizations ...
Breaking Medicine Technology:Kalorama: X-Ray and Digital X-Ray Market Nears 8 Billion This Year 2Kalorama: X-Ray and Digital X-Ray Market Nears 8 Billion This Year 3Alimera Sciences Announces Agreement with Deerfield Management for $50.0 Million Financing 2Alimera Sciences Announces Agreement with Deerfield Management for $50.0 Million Financing 3Mercy Health System, Janesville Police / Fire, provide casualty training to high school faculty 2Mercy Health System, Janesville Police / Fire, provide casualty training to high school faculty 3
... Tissues at Well-Tolerated ... Doses, ... data from a phase 1 dose-escalation trial of XL765, a,novel small molecule ... proliferation, survival, and,resistance to chemotherapy and radiotherapy. The trial is being carried ...
... III clinical trial --, CHICAGO, May 31 ... the presentation of updated results from,a 482 patient, ... dexamethasone (VcD) to vincristine, adriamycin and,dexamethasone (VAD). Results ... in the VcD arm as induction therapy and ...
Cached Medicine Technology:Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO 2Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO 3Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO 4Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO 5VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 2VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 3VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 4VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 5VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 6
(Date:11/28/2014)... November 29, 2014 The holiday season is ... recently announced its new collection of fashionable party dresses. What’s ... off, on all these brand new outfits; the special offer ... is a renowned online supplier and it has received a ... new items are specially designed to flatter various body shapes; ...
(Date:11/28/2014)... Brosix is always making changes to ... with a more efficient, effective, and secure experience. Most ... , 1. The ability to setup local servers for ... better service customers around the globe. , 2. The ... large customers that require millions of users in one ...
(Date:11/28/2014)... November 28, 2014 Novatus, a ... its Release v5.1 which provides customers with greater ... options. , “As we continue to evolve ... provide more functionality and improved performance in response ... CEO for Novatus. “With the enhancements that we ...
(Date:11/28/2014)... Diane Walder, one of South Florida’s top cosmetic dermatologists ... Ultrashape that is designed to help her patients reduce unwanted ... Ultrashape has been praised by patients as being permanent, painless, ... other types of external fat reduction. , “If you can ... , According to Dr. Walder, Ultrashape works by targeting subcutaneous ...
(Date:11/28/2014)... Minnesota (PRWEB) November 28, 2014 ... of the few insurance marketing organizations in the ... income and asset protection marketplace. Secura Consultants is ... partnership with Principal Financial Group, a leading global ... multiple ownership interests. With the ownership interest comes ...
Breaking Medicine News(10 mins):Health News:Trendy Party Dresses For The Coming Holiday Season From Balfleet.com 2Health News:Brosix Infrastructure Architecture Changes to Benefit Users 2Health News:Novatus Releases v5.1 with New Advanced Reporting Capabilities 2Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 2Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 3Health News:Secura Consultants Offers Complimentary Buy-Sell Agreement Reviews 2
... The following is being,issued by the Democratic ... Marca Bristo, former Chair of the National Council ... held a conference call today in,advance of John ... on,Disability Issues in Columbus, Ohio. There is speculation ...
... results -, LAVAL, QC, July 25 /PRNewswire-FirstCall/ - ... will host a conference call on,Friday, August 8 at ... results. Labopharm will report its second quarter 2008 financial,results ... day., To access the conference call by telephone, ...
... Impaired immune response after antiretroviral therapy may be due ... -- A new study challenges the long-held belief that ... ability to restore itself after HIV patients are treated ... percent to 90 percent of HIV-infected drug users are ...
... July 25, 2008 The American Society for ... of endoscopy in the bariatric surgery patient. The rising ... success in surgical interventions led to a marked increase ... U.S., from 13,365 in 1998 to 102,794 in 2003. ...
... of jobs created in the medical field slowed in June, pharmaceutical companies ... June than in previous months. , ... Seattle, WA (PRWEB) July 25, ... slowed in June overall, pharmaceutical companies reported a different kind of slowdown ...
... -, CORONA, Calif., July 25 Watson,Pharmaceuticals, ... pharmaceutical,company, announced today that its subsidiary has commenced ... in the 40mg,strength from its Davie, Florida manufacturing ... days of marketing exclusivity for being the,first to ...
Cached Medicine News:Health News:AUDIO OF CONFERENCE CALL: National Disability Rights Leaders Dubious Over John McCain's Possible Switch on Community Choice Act, Says DNC 2Health News:Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET) 2Health News:Study Disproves Belief That Hepatitis C Blunts HIV Drugs 2Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 2Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 3Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 2Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 3Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2
... Bulb Direct has been selling ... since 1996, and we are ... satisfaction guarantee. Check out our ... see our discount light bulbs ...
... has been selling replacement bulbs ... and we are extremely proud ... Check out our catalog of ... discount light bulbs specials. ...
... Bulb Direct has been ... Internet since 1996, and we ... 100% satisfaction guarantee. Check out ... and see our discount light ...
... Bulb Direct has been ... Internet since 1996, and we ... 100% satisfaction guarantee. Check out ... and see our discount light ...
Medicine Products: